The one regulatory item for the desk today is a new American College of Gastroenterology clinical guideline on the diagnosis and management of hereditary adenomatous colorectal polyposis syndromes, developed using GRADE methodology and focused on the two commonest, familial adenomatous polyposis and MUTYH-associated polyposis.
The document covers the full pathway: who should undergo risk assessment based on personal and family history, the modality and timing of germline genetic testing, endoscopic and surgical risk mitigation, and the role of chemoprevention. It deals separately with management guided by genetic results and management where testing has not been done — which matters, because that second situation is the common one outside well-resourced systems. It also addresses presymptomatic diagnosis in families with a known pathogenic variant, and reviews the extracolonic manifestations that get missed when attention stays on the colon: duodenal, ampullary and gastric cancer risk in particular.
That extracolonic point is the one most worth carrying away for a general oncology clinic. A patient with familial adenomatous polyposis who has had a colectomy is often regarded as having had their cancer risk dealt with. They have not — duodenal and ampullary surveillance remains necessary, and desmoid disease remains a major cause of morbidity after surgery.
For Indian practice, where germline testing is available but rarely funded and family history is frequently incomplete, the section on managing phenotypic polyposis without a genetic diagnosis is the most immediately applicable part. The other action is more mundane and more neglected: when a polyposis syndrome is identified, cascade testing of relatives is where most of the preventable cancer sits, and it depends on someone taking responsibility for contacting the family.
- Review your risk-assessment triggers against the updated criteria for who warrants germline testing.
- Continue upper gastrointestinal surveillance after colectomy — duodenal and ampullary risk persists.
- Use the guidance on managing phenotypic polyposis where genetic testing is unavailable.
- Assign responsibility for cascade testing of relatives; this is where preventable cancer is found.
- Remember desmoid disease as a major source of post-surgical morbidity in familial adenomatous polyposis.
The statistics, in plain English
GRADE methodology separates the strength of a recommendation from the certainty of the evidence behind it, which matters a lot in this field. Hereditary polyposis syndromes are rare, so almost none of the surveillance intervals or surgical thresholds rest on randomised evidence — they rest on cohort data and expert judgement about cancer risk over decades. A strong recommendation with low-certainty evidence is common here and is not a contradiction: it reflects that the consequences of missing a cancer are severe enough to act on imperfect data.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free